Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)
This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by DNAtrix, Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
First received: June 9, 2016
Last updated: March 10, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is currently recruiting participants.|
|Estimated Study Completion Date:||June 2020|
|Estimated Primary Completion Date:||December 2019 (Final data collection date for primary outcome measure)|